Next Gen 1 is under clinical development by Bioprojet SCR and currently in Phase I for Narcolepsy. According to GlobalData, Phase I drugs for Narcolepsy have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Next Gen 1’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Next Gen 1 overview

The therapeutic candidates (pitolisant assets) are under development for the treatment of narcolepsy and unspecified neurological diseases. They act by targeting histamine-3 receptor (H3R).

Bioprojet SCR overview

Bioprojet SCR (Bioprojet) is a research institute that carries out the development and marketing of pharmaceutical products. The company’s activities include the design and assessment of drugs, with a focus on creating pharmacological drug classes. Its products include adrenaline (injectable solution in pre-filled syringe), anhydrous sodium clodronate (film-coated tablet), clevidipine (emulsion for injection), oral rehydration solution, helicobacter test infai, treprostinil (solution for perfusion), racecadotril and pitolisant (film-coated tablet). The company’s products are used to treat various conditions such as narcolepsy, alcohol use disorder, restless legs syndrome and eosinophilic oesophagitis. The company works in collaboration with Acino, a Swiss pharmaceutical distributor, for the registration, marketing and distribution of products. Bioprojet operates in various countries including France, the UK, Italy, Germany, Spain, the Benelux and Tunisia. Bioprojet is headquartered in Paris, Ile-de-Franc, France.

For a complete picture of Next Gen 1’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.